FAM86C1P: A Potential Drug Target and Biomarker for the Treatment of Human Cancer

Target Name: FAM86C1P

NCBI ID: G55199

FAM86C1P

FAM86C1P: A Potential Drug Target and Biomarker for the Treatment of Human Cancer

Abstract:

FAM86C1P (F86C1_HUMAN) is a gene that encodes a protein known as FAM86C1. This gene has been identified as a potential drug target and biomarker for the treatment of human cancer. The FAM86C1 protein is known to play a crucial role in the development and progression of various types of cancer. Therefore, targeting the FAM86C1 protein using small molecules or antibodies has the potential to provide new treatments for cancer.

Introduction:

Cancer is a leading cause of death worldwide, with over 20 million people succumbing to the disease. The development and progression of cancer is a complex process that involves the interplay of multiple genetic and epigenetic factors. One of the key genetic factors that has been identified as a potential drug target is the FAM86C1 protein.

The FAM86C1 protein is a transmembrane protein that is expressed in various tissues and cells of the body. It is known to play a critical role in the development and progression of various types of cancer, including breast, ovarian, and colorectal cancers. The FAM86C1 protein is associated with the development of cancer-related alterations in gene expression, including the upregulation of pro-inflammatory and oncogenic signaling pathways.

FAM86C1P is a unique gene that encodes the FAM86C1 protein. It is expressed in various tissues and cells of the body, including the brain, heart, liver, and cancer cells. The FAM86C1P gene has been shown to be involved in the development and progression of cancer. Therefore, targeting the FAM86C1P protein using small molecules or antibodies has the potential to provide new treatments for cancer.

Targeting FAM86C1P:

The FAM86C1P protein is a potential drug target that can be targeted using various approaches, including small molecules and antibodies. One approach to targeting the FAM86C1P protein is to use small molecules that can inhibit the FAM86C1P protein's activity.

Anti-FAM86C1P antibodies have been shown to be effective in targeting the FAM86C1P protein and inhibiting its activity. These antibodies are derived from various sources, including monoclonal antibodies, polyclonal antibodies, and chimeric antibodies. The antibodies are designed to recognize specific epitopes on the FAM86C1P protein that are involved in its activity.

Another approach to targeting the FAM86C1P protein is to use small molecules that can bind to the FAM86C1P protein and prevent it from interacting with its downstream targets. This approach is based on the concept of \"inhibition-based\" targeting, where small molecules are used to disrupt the interactions between the FAM86C1P protein and its downstream targets.

Mechanism of Action:

The FAM86C1P protein is involved in various signaling pathways that are involved in the development and progression of cancer. Therefore, targeting its activity has the potential to disrupt the signaling pathways that contribute to cancer growth and progression.

The FAM86C1P protein is involved in the TGF-β signaling pathway, which is a key signaling pathway that is involved in the development and progression of cancer. The FAM86C1P protein is known to play a role in the regulation of TGF-β signaling by inhibiting the activity of the transcription factor SMAD.

The FAM86C1P protein is also involved in the PI3K/AKT signaling pathway, which is

Protein Name: Family With Sequence Similarity 86 Member C1, Pseudogene

The "FAM86C1P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM86C1P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets